Efficacy of nystatin vaginal effervescent tablets and nifuratel tablet combined with recombinant human interferon alpha 2b suppository in the treatment of candida vaginitis

Objective To explore the efficacy of nystatin vaginal effervescent tablets, nifuratel tablet combined with recombinant human interferon alpha 2b suppository in the treatment of candida vaginitis. Methods 124 patients with candida vaginitis were selected as the research subjects.The patients were randomly divided into two groups according to different treatment.The control group was treated with nystatin vaginal effervescent tablets + nifuratel tablet, the study group was given recombinant human interferon alpha 2b suppository on the basis of the control group.The symptoms, clinical curative effect, quality of life score, adverse reaction rate were observed and compared in the two groups. Results There were no statistically significant differences between the two groups in symptom and physical signs before treatment(all P>0.05). After treatment, the vulvar itching, burning pain, abnormal leucorrhea, redness symptoms and signs of the study group were (0.95±0.44)points, (1.02±0.51)points, (1.13±0.62)points, (1.09±0.56)points, which were significantly lower than those of the control group[(1.42±0.98)points, (1.28±1.02)points, (1.38±1.17)points, (1.37±1.12)points, t=2.529, 2.512, 2.505, 2.618, all P<0.05]. The total effective rate of the study group was 95.2%, which was significantly higher than 74.2% of the control group (Z=-2.839, P<0.05). After treatment, the quality of life scores of physiological function, bodily pain, mental health, emotional function and social function in the study group were (80.16±9.23)points, (84.22±9.95)points, (87.49±10.46)points, (89.27±12.35)points, (88.21±11.74)points, which were significantly higher than those in the control group[(67.58±5.34)points, (71.49±7.28)points, (73.52±7.61)points, (76.83±8.32)points, (75.51±8.16) points, t=9.728, 8.577, 9.036, 7.039, 7.537, all P<0.05]. The incidence rate of adverse reactions of the study group was significantly lower than that of the control group(χ2=10.978, P<0.05). Conclusion Nystatin vaginal effervescent tablets, nifuratel tablet combined with recombinant human interferon alpha 2b suppository in the treatment of candida vaginitis can significantly improve clinical symptoms, improve the therapeutic effect, and improve the quality of life of patients with significant clinical value, it is worthy of reference. Key words: Candidiasis, vulvovaginal; Nystatin; Nifuratel; Interferon alpha 2b